176 related articles for article (PubMed ID: 29132255)
1. Selected Radiation Safety Aspects Including Transportation and Lodging After Outpatient
Gomes-Lima CJ; Wu D; Kharazi PH; Khojekar GJ; Ringel MD; Vetter RJ; Bloom G; Burman KD; Wartofsky L; Van Nostrand D
Thyroid; 2017 Dec; 27(12):1558-1565. PubMed ID: 29132255
[TBL] [Abstract][Full Text] [Related]
2. Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After
Wu D; Gomes Lima CJ; Bloom G; Burman KD; Wartofsky L; Van Nostrand D
J Nucl Med; 2020 Mar; 61(3):397-404. PubMed ID: 31451488
[TBL] [Abstract][Full Text] [Related]
3. Current safety practices relating to I-131 administration for diseases of the thyroid: a survey of physicians and allied practitioners.
Greenlee C; Burmeister LA; Butler RS; Edinboro CH; Morrison SM; Milas M;
Thyroid; 2011 Feb; 21(2):151-60. PubMed ID: 21275765
[TBL] [Abstract][Full Text] [Related]
4. Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma.
Grigsby PW; Siegel BA; Baker S; Eichling JO
JAMA; 2000 May; 283(17):2272-4. PubMed ID: 10807387
[TBL] [Abstract][Full Text] [Related]
5. Treatment of thyroid carcinoma: emphasis on high-dose 131I outpatient therapy.
Parthasarathy KL; Crawford ES
J Nucl Med Technol; 2002 Dec; 30(4):165-71; quiz 172-3. PubMed ID: 12446749
[TBL] [Abstract][Full Text] [Related]
6. Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure.
Willegaignon J; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
Clin Nucl Med; 2011 Jun; 36(6):440-5. PubMed ID: 21552020
[TBL] [Abstract][Full Text] [Related]
7. Thyroid remnant ablation with 1110MBq of 131I in outpatients: measurement of effective dose to household members and establishment of safety precautions.
Yoshimura M; Tsutsui H; Ikeda N; Koizumi K
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):101-8. PubMed ID: 23474638
[TBL] [Abstract][Full Text] [Related]
8. Outpatient treatment of thyroid cancer using high doses of iodine 131.
Caldwell CB; Ehrlich LE
Can Assoc Radiol J; 1999 Oct; 50(5):331-6. PubMed ID: 10555509
[TBL] [Abstract][Full Text] [Related]
9. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
de Carvalho JW; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
Nucl Med Commun; 2009 Jul; 30(7):533-41. PubMed ID: 19436231
[TBL] [Abstract][Full Text] [Related]
10. Outpatient therapeutic 131I for thyroid cancer.
Panzegrau B; Gordon L; Goudy GH
J Nucl Med Technol; 2005 Mar; 33(1):28-30. PubMed ID: 15731017
[TBL] [Abstract][Full Text] [Related]
11. Radioprotection using iodine-131 for thyroid cancer and hyperthyroidism: a review.
Al-Shakhrah IA
Clin J Oncol Nurs; 2008 Dec; 12(6):905-12. PubMed ID: 19064384
[TBL] [Abstract][Full Text] [Related]
12. Radiation Dose-rate Reduction Pattern in Well-differentiated Thyroid Cancer Treated with I-131.
Khan SA; Khan MS; Arif M; Durr-e-Sabih ; Rahim MK; Ahmad I
J Coll Physicians Surg Pak; 2015 Jul; 25(7):510-3. PubMed ID: 26208555
[TBL] [Abstract][Full Text] [Related]
13. Detection at Public Facilities of
Bikas A; Wu D; Bethancourt E; Orquiza M; Bloom G; Burman KD; Wartofsky L; Van Nostrand D
J Nucl Med; 2019 May; 60(5):638-643. PubMed ID: 30361377
[TBL] [Abstract][Full Text] [Related]
14. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association.
; Sisson JC; Freitas J; McDougall IR; Dauer LT; Hurley JR; Brierley JD; Edinboro CH; Rosenthal D; Thomas MJ; Wexler JA; Asamoah E; Avram AM; Milas M; Greenlee C
Thyroid; 2011 Apr; 21(4):335-46. PubMed ID: 21417738
[TBL] [Abstract][Full Text] [Related]
15. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
[TBL] [Abstract][Full Text] [Related]
16. Thyroid remnant ablation using 1,110 MBq of I-131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine therapy.
Kusakabe K; Yokoyama K; Ito K; Shibuya H; Kinuya S; Ito M; Higashi T; Togawa T; Koizumi K; Yoshimura M; Uchiyama M; Okamoto T; Kanaya S; Kanaya K; Yoneyama T; Ikebuchi H; Yanagida S; Shibata K; Segawa K; Yamamoto A
Ann Nucl Med; 2012 May; 26(4):370-8. PubMed ID: 22450825
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
18. [Role of radioactive iodine in the treatment of differentiated thyroid cancer: physiopathological basis, results, considerations from the viewpoint of radioprotection].
Frühling J
Bull Mem Acad R Med Belg; 1994; 149(3-4):195-206; discussion 206-8. PubMed ID: 7841930
[TBL] [Abstract][Full Text] [Related]
19. Radioactive iodine therapy for malignant and benign thyroid disease: a Canadian national survey of physician practice.
Demeter S; Leslie WD; Levin DP
Nucl Med Commun; 2005 Jul; 26(7):613-21. PubMed ID: 15942482
[TBL] [Abstract][Full Text] [Related]
20. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
